NASDAQ
Adaptimmune Therapeutics plc (ADAP) has a fcf yield of -55.86% as of Friday, May 29, 2026. This represents a 30.44% decrease compared to its 12-month average of -42.83%. Free cash flow yield measures free cash flow per share as a percentage of the stock price, indicating cash return potential.
No price data available for this timeframe.